CARL
Carlsmed, Inc.
Healthcare — Health Information Services
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
None
6 analysts
$13.76
$-0.31 (-2.20%)
Target:
$18.17
(32.0%)
Price History
52-Week Range
Sign in to add CARL to a watchlist or set price alerts.
Fundamentals
| Market Cap | $318.34M |
| P/E Ratio (TTM) | - |
| Forward P/E | -8.16 |
| EPS (TTM) | $-0.98 |
| Dividend Yield | - |
| Profit Margin | -57.76% |
| Revenue Growth | 58.20% |
| ROE | -52.43% |
| Debt/Equity | 18.71 |
| Recommendation | None |
| Analyst Target | $18.17 |
| Analysts | 6 |
| Next Earnings | Aug 5, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 51.9 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $17.19 |
| 52-Week Low | $8.50 |
| 50-Day Avg | $10.65 |
| 200-Day Avg | $12.12 |
| Avg Volume | 147.5K |
| Volume | 59.2K |
Performance Analysis
BULLISHCARL shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 61% of its 52-week range.
~
RSI at 51.9 is in neutral territory.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Strong revenue growth of 58.2% year-over-year.
-
Operating at a loss with -57.8% margin.
~
Wall Street consensus is "none" from 6 analysts.
+
Average analyst target of $18.17 implies 32.0% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:01 UTC
Back to Screener Export Report